INT199691

From wiki-pain
Revision as of 16:23, 21 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.19
First Reported 2006
Last Reported 2006
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 3
Disease Relevance 1.52
Pain Relevance 0.21

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

molecular_function (2610029G23Rik) cellular_component (2610029G23Rik) biological_process (2610029G23Rik)
Anatomy Link Frequency
liver 1
2610029G23Rik (Mus musculus)
Pain Link Frequency Relevance Heat
anesthesia 9 88.40 High High
Bioavailability 3 85.48 High High
Potency 9 5.00 Very Low Very Low Very Low
imagery 9 5.00 Very Low Very Low Very Low
ketamine 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Body Weight 9 96.44 Very High Very High Very High
Mycobacterial Infection 372 93.12 High High
Acquired Immune Deficiency Syndrome Or Hiv Infection 66 91.28 High High
Disease 6 68.28 Quite High
Infection 30 32.96 Quite Low
Sprains And Strains 45 5.00 Very Low Very Low Very Low
Death 6 5.00 Very Low Very Low Very Low
Exsanguination 3 5.00 Very Low Very Low Very Low
Bacterial Infection 3 5.00 Very Low Very Low Very Low
Cancer 3 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The test regimens were then administered orally for 2 mo in the combination of OPC-67683, RFP, and PZA, or RFP, INH, EB, and PZA as an intensive treatment, and for an additional 2 mo in the combination of OPC-67683 and RFP or 4 mo in the combination of RFP and INH as a maintenance treatment.
Localization (combination) of OPC-67683
1) Confidence 0.19 Published 2006 Journal PLoS Medicine Section Body Doc Link PMC1664607 Disease Relevance 0.49 Pain Relevance 0.09
Our results showed that OPC-67683 was hardly metabolized when exposed to human and animal liver microsomes and did not have inductive, stimulatory, or inhibitory effects on CYP enzyme activities at concentrations up to 100 ?
Localization (metabolized) of OPC-67683 in liver
2) Confidence 0.19 Published 2006 Journal PLoS Medicine Section Body Doc Link PMC1664607 Disease Relevance 0.57 Pain Relevance 0.04
The test regimens were then administered orally for 2 mo in the combination of OPC-67683, RFP, and PZA, or RFP, INH, EB, and PZA as an intensive treatment, and for an additional 2 mo in the combination of OPC-67683 and RFP or 4 mo in the combination of RFP and INH as a maintenance treatment.
Localization (combination) of OPC-67683
3) Confidence 0.19 Published 2006 Journal PLoS Medicine Section Body Doc Link PMC1664607 Disease Relevance 0.46 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox